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 In recent years there has been unprecedented interest from commercial sectors, the 16 
public, veterinary clinicians and researchers in the use of stem cells as therapy for an 17 
array of diseases in companion animals 18 
 Several therapeutic applications of stem cells are already employed in a clinical 19 
setting, in particular the use of mesenchymal stem cells to treat osteoarthritis in horses 20 
and dogs 21 
 However, an assessment of the scientific literature highlights a marked disparity 22 
between the purported benefits of stem cell therapies and their proven abilities as 23 
defined by rigorously controlled scientific studies 24 
 Thus, while the preliminary data generated from clinical trials in human patients are 25 
encouraging, current therapies on offer to veterinary patients are supported by very 26 
limited clinical data and the commercialisation of these therapies is perhaps premature 27 
 This review introduces the three main types of stem cells relevant to veterinary 28 
applications – embryonic stem cells, induced pluripotent stem cells and mesenchymal 29 
stem cells – and draws together the research findings from in vitro and in vivo studies 30 
to give an overview of the current state-of-play of stem cell therapies for treating 31 
osteoarthritis in veterinary medicine 32 
 The review concludes by discussing recent advances in tissue engineering, which is 33 









There has been unprecedented interest in recent years in the use of stem cells as therapy 40 
for an array of diseases in companion animals. Stem cells have already been deployed 41 
therapeutically in a number of clinical settings, in particular the use of mesenchymal stem 42 
cells to treat osteoarthritis in horses and dogs. However, an assessment of the scientific 43 
literature highlights a marked disparity between the purported benefits of stem cell therapies 44 
and their proven abilities as defined by rigorously controlled scientific studies.  45 
 46 
Although preliminary data generated from clinical trials in human patients are 47 
encouraging, therapies currently available to treat animals are supported by very limited 48 
clinical evidence, and the commercialisation of these treatments may be premature. This 49 
review introduces the three main types of stem cells relevant to veterinary applications, 50 
namely, embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells, 51 
and draws together research findings from in vitro and in vivo studies to give an overview of 52 
current stem cell therapies for the treatment of osteoarthritis in animals. Recent advances in 53 
tissue engineering, which is proposed as the future direction of stem cell-based therapy for 54 
osteoarthritis, are also discussed. 55 
 56 
Keywords: Mesenchymal stem cells; Induced pluripotent stem cells; Embryonic stem cells; 57 
Osteoarthritis; Tissue engineering  58 




Stem cell biology and the identification of veterinary applications comprise a rapidly 60 
developing field of research driven by the growing significance of cats and dogs as 61 
companion animals, the economic impact of the horse industry, and the recognition that many 62 
human diseases have counterparts in companion animals. Several commercial companies 63 
around the world offer stem cell preparations as regenerative therapy for osteoarthritis in 64 
dogs and horses, and in the treatment of ligament and tendon injuries in horses. A 65 
contributing factor to the proliferation of veterinary stem cell-based applications is that the 66 
use of such therapies in animals is not regulated in any of the countries in which they are 67 
offered. A further concern is the fact that the efficacy of these therapies is frequently not 68 
supported by published data. 69 
 70 
We review below the main types of stem cells, with particular attention to 71 
mesenchymal stem cells (MSCs), which have been used most extensively in veterinary 72 
applications. The current main therapeutic use of stem cells in the treatment of osteoarthritis 73 
in animals will then be reviewed, and recent advances in tissue engineering, which uses a 74 
potent combination of biomaterials and stimulatory factors to deliver stem cells and to direct 75 
their differentiation, will be discussed. The latter likely represents a key process in the future 76 
application of effective stem cell-based therapies for companion animals, as it circumvents 77 
the current practice of delivering cell suspensions that fail to provide any long term 78 
engraftment of cells. 79 
 80 
Types of stem cells 81 
Generally speaking, stem cells can be divided into two main classes: embryonic and 82 
adult. Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocyst 83 
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stage embryo. Given that these cells will give rise to the embryo proper, they exhibit the 84 
unique property of pluripotency; that is, they have the potential to differentiate into all of the 85 
various cell types that constitute the adult individual (Fig. 1). A further defining feature of 86 
ESCs is that they are immortal and under in vitro culture conditions are capable of indefinite 87 
proliferation without undergoing differentiation, a property known as self-renewal.  88 
 89 
Adult stem cells, by contrast, are found within the majority of tissues, where they play a 90 
role in tissue maintenance and repair. The adult stem cells that hold the greatest therapeutic 91 
potential, and so have attracted significant research interest, are the MSCs, also known as 92 
mesenchymal stromal cells (Fig. 1). A third category of stem cell, which is neither 93 
‘embryonic’ nor ‘adult’, is the induced pluripotent stem cell (iPSC) (Fig. 1). These stem cells 94 
are unique in that they are essentially manufactured from adult, terminally differentiated, 95 
cells such as fibroblasts via a process of ‘re-programming’. 96 
 97 
Stem cells as a therapeutic resource 98 
Embryonic stem cells 99 
Given their properties of self-renewal and pluripotency, ESCs offer the possibility of an 100 
unlimited, renewable source of cells that can be induced to differentiate into any cell of the 101 
body and so hold substantial appeal as a therapeutic resource. While ESCs from mice and 102 
humans have been characterised extensively, and the optimal conditions elucidated for their 103 
derivation and maintenance in vitro, the same cannot be said for ESCs derived from 104 
companion animals. 105 
 106 
Several authors have described the establishment of canine ESCs (Hatoya et al., 2006; 107 
Schneider et al., 2007; Hayes et al., 2008; Vaags et al., 2009; Wilcox et al., 2009); however, 108 
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there appear to be significant differences between the individual lines of canine ESCs in 109 
terms of morphology, demonstrable pluripotency (i.e. whether they can they differentiate into 110 
derivatives from all three embryonic germ layers), and their ability to be maintained in vitro. 111 
Similar problems have been encountered in ESCs isolated from the horse (Saito et al., 2002; 112 
Li et al., 2006) and cat (Yu et al., 2009). In part, these difficulties may be attributed to the 113 
differences in the patterns of embryonic development between species, but also to our lack of 114 
understanding of the specific culture conditions required for maintaining these cells in their 115 
pluripotent state (i.e. preventing them from differentiating). For example, the culture 116 
conditions required for mouse and human ESCs differ substantially, not least in the growth 117 
factors required for their survival and proliferation (Pera and Tam, 2010). 118 
 119 
Since equine ESCs have become commercially available, their use has been 120 
demonstrated through effecting significant healing of experimentally induced lesions in the 121 
equine superficial digital flexor tendon (Watts et al., 2011). Currently, these ESCs are the 122 
only cells of this type of any species commercially available to veterinarians for therapeutic 123 
applications. However, it remains possible that the use of ESCs as a therapeutic resource is 124 
compromised by one of the very factors that, on initial consideration, would appear to be a 125 
compelling reason for their use, namely, their pluripotency.  126 
 127 
The ability of ESCs to differentiate into any cell type when harnessed and driven to a 128 
specific end-point is the essence of their curative potential. However, if not tightly controlled, 129 
this property has the potential to create disease in the form of teratomas, tumours that develop 130 
from pluripotent cells and that contain cells derived from all three embryonic germ layers. 131 
Ensuring that transplanted ESCs differentiate along a specific pathway, and do not form 132 
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undesired tissue (e.g. bone at the articular surface of a joint), is one of the major challenges 133 
facing the use of ESCs in both humans and animals. 134 
 135 
Induced pluripotent stem cells 136 
The advent of induced pluripotent stem cells (iPSCs) has significantly advanced the 137 
prospects of stem cell-based therapies in humans and companion animals (Takahashi and 138 
Yamanaka, 2006). These stem cells are generated from adult, terminally differentiated cells, 139 
such as fibroblasts, following the introduction of four genes central to the regulation of 140 
pluripotency in mammalian cells, Oct4, Sox2, cMyc and Klf4. The induced expression of 141 
these pluripotency factors re-programmes differentiated cells into stem cells with properties 142 
very similar to those of ESCs.  143 
 144 
iPSCs have been generated from a variety of companion and domestic animal species, 145 
including dogs (Shimada et al., 2010; Lee et al., 2011; Luo et al., 2011; Whitworth et al., 146 
2012), horses (Nagy et al., 2011; Breton et al., 2013; Whitworth et al., 2014a), pigs (Esteban 147 
et al., 2009; Ezashi et al., 2009; Wu et al., 2009), sheep (Bao et al., 2011; Li et al., 2011; Liu 148 
et al., 2012; Sartori et al., 2012), cattle (Han et al., 2011; Sumer at al., 2011; Cao et al., 2012), 149 
and buffaloes (Deng et al., 2012). 150 
 151 
Since iPSCs can be generated from nominated individuals (typically from a small skin 152 
biopsy) it is possible to produce iPSCs from individuals with a specific disease or genetic 153 
background. Thus, iPSCs can be used to model diseases in vitro, serve as a platform for drug 154 
screening and be manipulated with gene correction strategies for transplantation back into the 155 
donor. Furthermore, because iPSCs can be produced from a patient’s own cells, they have the 156 
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potential to serve as a renewable source of cells for regenerative therapies as required by that 157 
individual. 158 
 159 
However, several obstacles need to be overcome before iPSCs can be used safely in 160 
cell-based therapies. Traditionally, cells have been re-programmed using lentiviruses or 161 
retroviruses to deliver the re-programming factors as transgenes, resulting in both the 162 
backbone of the viral vector and the re-programming transgenes becoming incorporated into 163 
the recipient cells’ genome. These insertions have the potential to cause mutations (Yu et al., 164 
2007) and, in some instances, the transgenes encoding the re-programming factors may not 165 
be silenced, or may become reactivated, which can result in the formation of teratomas (Okita 166 
et al., 2007). Consequently, virally re-programmed cells are not suitable for clinical 167 
applications.  168 
 169 
Several strategies have been developed to enable transient expression of the re-170 
programming factors without them becoming integrated into the recipient cells’ genome. 171 
These include the use of adenoviruses (Stadtfeld et al., 2008), Sendai virus (Fusaki et al., 172 
2009), piggyBac transposons (Woltjen et al., 2009; Yusa et al., 2009) and episomal plasmids 173 
(Okita et al., 2008) to deliver the transgenes and, more recently, transducing the cells with 174 
synthetic modified messenger RNAs encoding the re-programming factors (Mandal and 175 
Rossi, 2013). 176 
 177 
Re-programming strategy aside, the acquisition of pluripotency poses the same double-178 
edged sword for the clinical use of iPSCs as it does for ESCs. Specifically, given their 179 
pluripotency, iPSCs carry the same risk of tumourigenesis as ESCs when transplanted. This 180 
problem could be circumvented by fully differentiating the cells before transplantation and 181 
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then identifying and destroying any residual pluripotent cells from the graft. Although several 182 
methods have been developed, the efficacy of these to prevent the formation of teratomas in 183 
vivo remains unproven (Wu and Hochedlinger, 2011). 184 
 185 
Mesenchymal stem cells 186 
MSCs are multipotent cells capable of differentiating into bone, cartilage and adipose 187 
tissue (Pittenger et al., 1999). Recent studies have demonstrated that they are also able to 188 
form pancreatic islet cells (Santos et al., 2010), hepatocytes (Lee et al., 2004; Ong et al., 189 
2006) and neurons (Woodbury et al., 2000) in vitro. In humans, MSCs are typically isolated 190 
from adult bone marrow and adipose tissue (Kern et al., 2006; Bieback et al., 2008) but they 191 
have also been successfully collected from placenta (In't Anker et al., 2004), umbilical cord 192 
blood (Kern et al., 2006) and amniotic fluid (In't Anker et al., 2004; Tsai et al., 2004) in 193 
addition to various fetal tissues, such as kidney (Al-Awqati and Oliver, 2002), pancreas (Hu 194 
et al., 2003), liver (Campagnoli et al., 2001; In’t Anker et al., 2003) as well as lung and 195 
spleen (In’t Anker et al., 2003). 196 
 197 
Many studies have described the isolation of MSCs from a range of canine tissues, 198 
including adipose tissue (Neupane et al., 2008; Vieira et al., 2010; Kisiel et al., 2012; Reich et 199 
al., 2012; Takemitsu et al., 2012), bone marrow (Kisiel et al., 2012; Reich et al., 2012; 200 
Takemitsu et al., 2012), muscle (Kisiel et al., 2012), periosteum (Kisiel et al., 2012) and 201 
synovium (Zhang et al., 2013). Similarly diverse sources have been identified for equine 202 
MSCs (Hegewald et al., 2004; Koch et al., 2007; Crovace et al., 2010; Raabe et al., 2011; 203 
Ranera et al., 2012; Burk et al., 2013; Barberini et al., 2014; De Schauwer et al., 2014), as 204 
well as caprine (Murphy et al., 2003), ovine (Jager et al., 2006; Mrozik et al., 2010) and 205 
porcine (Wang et al., 2008; Cao et al., 2011; Miernik and Karasinski, 2012). 206 




An important feature of MSCs that has enhanced their clinical appeal is that they are 208 
thought to be immune privileged, most likely due to an absence of MHC class II expression 209 
(DiMarino et al., 2013). In domestic species, both canine and equine MSCs appear to lack 210 
expression of MHC class II (Wood et al., 2012; Barberini et al., 2014; De Schauwer et al., 211 
2014). In contrast, Schnabel et al. (2014) found equine bone marrow-derived MSCs to have 212 
marked heterogeneity in their expression of MHC class II, and that MSCs initially identified 213 
as being MHC class II negative can potentially upregulate MHC class II expression when 214 
placed into an environment of active inflammation. 215 
 216 
MSCs are themselves immunomodulatory and are potent regulators of inflammation, 217 
seemingly through their active suppression of both the innate and adaptive immune systems 218 
(Griffin et al., 2010). MSCs have been shown to regulate the proliferation and function of a 219 
variety of immune cells, including B and T lymphocytes, natural killer cells, neutrophils and 220 
dendritic cells (Griffin et al., 2010). Equine MSCs express transforming growth factor (TGF)-221 
β and hepatocyte growth factor (HGF), both of which suppress T lymphocyte proliferation 222 
(De Schauwer et al., 2014). MSCs also secrete a range of anti-fibrotic, anti-apoptotic, 223 
bactericidal and pro-angiogenic factors (DiMarino et al., 2013). This relative lack of 224 
immunogenicity, in addition to their immunomodulatory and anti-inflammatory properties, 225 
have made MSCs an ideal choice for allogeneic, ‘off-the-shelf’, stem cell therapies for 226 
diseases with an inflammatory, or immune-mediated, component including osteoarthritis. 227 
 228 
However, a common feature of MSCs, irrespective of species-of-origin, is that they 229 
represent a very small fraction of the cells isolated from both bone marrow and adipose tissue 230 
(0.001-0.01% and 0.05%, respectively) for human tissues (Kern et al., 2006; Bieback et al., 231 
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2008). Also, in both humans and dogs, the quality and quantity of MSCs that can be collected 232 
decline with increasing age of the donor (Stolzing et al., 2008; Zhou et al., 2008; Kisiel et al., 233 
2012; Guercio et al., 2013; Zhang et al., 2013) which has the potential to be problematic for 234 
regenerative therapies, such as those targeting osteoarthritis, where the majority of patients 235 
are aged. In contrast, human placental and fetal-derived MSCs have superior proliferative and 236 
differentiative abilities compared to MSCs from adult tissues (In't Anker et al., 2004; 237 
Gotherstrom et al., 2005; Guillot et al., 2007).  It remains to be determined whether this 238 
comparison holds true for MSCs collected from domestic species. 239 
 240 
In an attempt to circumvent the decreased capacity for proliferation and differentiation 241 
of adult MSCs, we and others (Lian et al., 2010; Chen et al., 2012; Whitworth et al., 2014b) 242 
have produced MSCs from iPSCs. In humans, these iPSC-derived MSCs resemble primary, 243 
tissue-sourced MSCs in terms of their immunophenotype and in their ability to differentiate 244 
into the mesodermal derivatives of cartilage, bone and adipose tissue (Lian et al., 2010; Chen 245 
et al., 2012). Using the methodology of Chen et al. (2012), we have generated canine iPSC-246 
derived MSCs that are highly proliferative and readily differentiate along the osteogenic, 247 
chondrogenic and adipogenic pathways (Whitworth et al., 2014b). The ability to efficiently 248 
derive large numbers of highly proliferative MSCs from iPSCs represents an important step 249 
towards being able to source sufficient cells of high osteogenic and chondrogenic ability for 250 
MSC-based therapies in both veterinary and human medicine. 251 
 252 
In summary, because of their strong propensity to form cartilage, relative ease of 253 
harvest from adult tissues, immune privileged status and anti-inflammatory effects, MSCs 254 
have been the focus of stem cell-based therapies targeting cartilage repair in veterinary and 255 
human patients with osteoarthritis. 256 




Can mesenchymal stem cells effect cartilage repair in animals with osteoarthritis? 258 
Many studies have been performed on a variety of animal species testing the efficacy of 259 
MSCs at repairing damaged cartilage in both naturally occurring and induced models of 260 
osteoarthritis. While space limitations prevent us from being able to discuss each published 261 
study, the salient points from each are summarised in Tables 1 and 2. However, it is 262 
important to consider key observations that can be extracted from the literature. 263 
 264 
Mesenchymal stem cells do not engraft into cartilage defects 265 
Current commercial MSC-based therapies for the treatment of osteoarthritis involve 266 
injecting a suspension of MSCs into the joint space. A study of the literature makes it 267 
apparent that MSCs introduced in this fashion do not engraft into the endogenous cartilage 268 
and directly affect repair. Desando et al. (2013) injected labelled MSCs into the stifle joints 269 
of rabbits with mild osteoarthritis. Joints were assessed at 3 and 20 days post-MSC transplant 270 
and, while labelled MSCs were detected in the synovial membrane and medial meniscus 271 
none, were seen in the cartilage. Similar engraftment of MSCs into the meniscus, but not the 272 
cartilage, was obtained by Hatsushika et al. (2013), also in rabbits.  273 
 274 
Using a goat model of osteoarthritis, Murphy et al. (2003) found that injected MSCs 275 
had engrafted in high numbers into the synovium, fat pad and lateral meniscus, but not the 276 
damaged cartilage. Further studies in mice (ter Huurne et al., 2012), rats (Horie et al., 2009) 277 
and miniature pigs (Pei et al., 2013) also describe a lack of engraftment of MSCs into 278 
cartilage defects. In a recent study in guinea pigs, a small number of labelled MSCs were 279 
detected within the osteoarthritic cartilage at 1 week after transplantation; however, by 5 280 
weeks, the cells had disappeared (Sato et al., 2012). A lack of engraftment has also been 281 
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observed in a horse model; McIlwraith et al. (2011) found no significant improvement in the 282 
healing of osteochondral defects in the stifle joints of horses treated with bone marrow-283 
derived MSCs compared to controls, except that MSC-treated joints showed an increase in 284 
the ‘firmness’ of the repair tissue, which was shown to have significantly greater levels of 285 
aggrecan, a component of articular cartilage. 286 
 287 
Mesenchymal stem cells may retard the progression of osteoarthritic lesions in the short term 288 
Whereas MSCs do not engraft within osteoarthritic lesions they do appear to have 289 
chondroprotective benefits, retarding the progression of cartilage destruction by reducing 290 
inflammation. In a rabbit model of osteoarthritis, joints treated with MSCs had reduced 291 
expression of tumour necrosis factor (TNF)-α, which is an inflammatory cytokine, and matrix 292 
metalloproteinase (MMP)-1 which degrades proteoglycans in cartilage (Desando et al., 293 
2013). In a mouse model of traumatic osteoarthritis, MSCs failed to induce regeneration of 294 
new cartilage, but they did mitigate the development of osteoarthritis during the 2 month 295 
study period (Diekman et al., 2013). In the horse, Frisbie et al. (2009) similarly observed no 296 
significant effects of MSCs on the repair of osteoarthritic lesions but did note reduced 297 
inflammation in the joints of horses treated with MSCs, further highlighting the anti-298 
inflammatory properties of MSCs (Frisbie et al., 2009). 299 
 300 
Similar results were described by Murphy et al. (2003) in the goat. At 20 weeks after 301 
the experimental group had received the MSC treatment, both controls and MSC-treated 302 
animals showed significant osteoarthritic lesions; however, the degree of cartilage 303 
destruction, osteophyte formation and subchondral sclerosis were reduced in 4/6 MSC-treated 304 
animals (Murphy et al., 2003). Again, this points to an anti-inflammatory, rather than 305 
regenerative, effect of the MSCs on the cartilage. An important additional point to note with 306 
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this study, and others that have involved a meniscectomy, is that while MSCs do not engraft 307 
within the cartilage, they do engraft within the meniscus, where they contribute to the 308 
development of new meniscal tissue (Horie et al., 2012). It is this ability to regenerate new 309 
meniscus that is at least partly responsible for the improved condition of the cartilage lesions 310 
in the MSC-treated groups, as shown by the study by Murphy et al. (2003) in the goat where 311 
the two MSC-treated animals that did not show a significant improvement in the cartilage 312 
lesions compared to controls also failed to grow new menisci. 313 
 314 
The timing of MSC treatment with respect to the onset of osteoarthritis also seems to be 315 
a key factor in the degree to which MSCs modulate the progression of cartilage destruction. 316 
In a mouse model of osteoarthritis, lesions were induced by injection of collagenase into the 317 
joint (ter Huurne et al., 2012). If MSCs were injected 7 days after the collagenase treatment, 318 
cartilage destruction was reduced by 35% compared to controls. However, if the delivery of 319 
MSCs was delayed until 14 days after the collagenase injection, there was no difference in 320 
cartilage lesions between the MSC-treated and control groups (ter Huurne et al., 2012). 321 
 322 
Given that MSCs do not engraft within the cartilage and appear to reside only 323 
transiently within the synovium, fat pad and menisci (Murphy et al., 2003; ter Huurne et al., 324 
2012; Desando et al., 2013), these anti-inflammatory effects would reasonably be expected to 325 
be short-lived. This is borne out in a study of dogs with osteoarthritis secondary to hip 326 
dysplasia, which were injected with autologous MSCs (Vilar et al., 2013). The dogs showed 327 
improved lameness up to 6 months after the injection of MSCs into the coxofemoral joint; 328 
however, at around 10 months after treatment, the dogs began showing signs of regression in 329 
lameness scores (Vilar et al., 2013). 330 
 331 
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A similar short-lived effect has been observed in the horse. Wilke et al. (2007) applied 332 
bone marrow-derived MSCs to induced full-thickness cartilage lesions at the femoropatellar 333 
articulation in adult horses. At 30 days post-MSC transplant, lesions that had been exposed to 334 
the MSCs had significantly better healing scores than controls, an effect that can probably be 335 
attributed to reduced inflammation. However, this observation was short-lived, since at 8 336 
months post-transplantation there were no histological, immunocytochemical or biochemical 337 
differences between the MSC-treated joints and the controls. 338 
 339 
Chondrogenic effects may be observed when scaffolds and pro-chondrogenic molecules are 340 
combined with mesenchymal stem cells 341 
While MSCs injected as a free suspension into the joint do not engraft into the 342 
cartilage, MSCs that are incorporated into support structures such as scaffolds, or combined 343 
with pro-chondrogenic molecules, such as hyaluronic acid (HA), appear to engraft and so 344 
contribute more significantly to cartilage repair. HA is an important component of the 345 
extracellular matrix of cartilage that has been shown, both in vitro and in vivo, to encourage 346 
the differentiation of MSCs into chondrocytes and to downregulate the expression of factors 347 
that degrade the cartilage matrix (Grigolo et al., 2009). 348 
 349 
Sato et al. (2012), using a guinea pig model of spontaneous OA, injected MSCs, MSCs 350 
and HA, or saline, into the affected joints. Guinea pigs that received MSCs alone showed no 351 
improvement in the damaged cartilage as compared to saline-injected controls, while guinea 352 
pigs that received MSCs in addition to HA showed some improvement in cartilage quality. In 353 
contrast, in a rabbit model of osteoarthritis, Kim et al. (2012) noted histological 354 
improvements of equal quality in the cartilage of rabbits treated with HA and MSCs, and 355 
those treated with HA alone. Similarly, Grigolo et al. (2009) also found that rabbits in which 356 
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HA-containing scaffolds were placed over the lesion showed signs of cartilage regeneration, 357 
albeit to a lesser degree than those rabbits that received the HA-containing scaffolds seeded 358 
with MSCs. 359 
 360 
Thus, most studies using MSCs in an attempt to repair damaged cartilage have involved 361 
injecting a suspension of MSCs into a joint space; at best this serves to retard the progression 362 
of osteoarthritis, most likely through paracrine anti-inflammatory effects, but does not 363 
generate any long-term physical repair of the cartilage, almost certainly because the MSCs 364 
fail to engraft. In contrast, studies in which the MSCs are spatially supported by a matrix 365 
(Fig. 2) show more promising results, especially when they are combined with biomaterials, 366 
such as HA, that support chondrogenesis. This, in essence, is tissue engineering: the 367 
combination of cells and biomaterials with a supporting matrix, or scaffold, in an attempt to 368 
regenerate damaged or diseased tissues. 369 
 370 
Tissue engineering 371 
Articular cartilage is a complex tissue consisting of four spatially distinct regions, each 372 
of which is characterised by a particular distribution of cells within an extracellular matrix of 373 
specific composition which, in turn, confer unique mechanical properties (Nguyen et al., 374 
2011). Given this complexity in structure, it is perhaps naïve to suppose that an injection of 375 
freely suspended cells into the joint space will recapitulate this complex tissue. Scaffolds, 376 
hydrogels and other matrices aim to organise the cells into a three-dimensional pattern that 377 
closely replicates that found in the endogenous tissue. In the case of cartilage, the goal is to 378 
induce MSCs to form the four distinct layers of articular cartilage and to mimic their 379 
mechanical properties.  380 
 381 
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Nguyen et al. (2011) encapsulated mouse MSCs into polyethylene glycol (PEG)-based 382 
hydrogels into which they incorporated various biomaterials to generate three distinct layers 383 
of different compositions. After 6 weeks in culture, they produced a cartilage product that 384 
possessed the spatially varying mechanical and biochemical properties of endogenous 385 
cartilage (Nguyen et al., 2011). This is an exciting development, because it holds the promise 386 
of using MSCs to engineer a cartilage that can anchor to the native subchondral bone via the 387 
calcified zone, provide a smooth articular surface at the superficial zone and withstand the 388 
normal compression and shearing forces present within the joint. 389 
 390 
An in vivo study using a rat model of osteoarthritis showed that when human ESCs 391 
were encapsulated into hydrogels incorporating HA they were able to repair full-thickness 392 
osteochondral defects with newly generated hyaline cartilage that was fully integrated with 393 
the surrounding native cartilage (Toh et al., 2010). In a similar study in the dog, canine MSCs 394 
seeded into bilayered scaffolds that induced separate (but integrated) layers of cartilage and 395 
bone development, were effective at repairing a large osteochondral defect in the articular 396 
surface of the femoral condyles (Yang et al., 2011). 397 
 398 
A recent study in the horse demonstrated the efficacy of MSCs, used in combination 399 
with scaffolds and bioactive molecules, in regenerating osteochondral defects in a large 400 
animal model. Seo et al. (2013) impregnated gelatin/β-tricalcium phosphate (GT) sponges 401 
with bone marrow-derived MSCs and bone morphogenetic protein (BMP)-2, which 402 
stimulates osteogenesis, and inserted them into a full-thickness osteochondral defect in the 403 
lateral trochlear ridge of the talus. On top of this sponge, they then placed a second GT 404 
sponge loaded with chondrocytes, bone marrow-derived MSCs and platelet-rich plasma. 405 
After 4 months post-transplantation, a statistically significant repair in the osteochondral 406 
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defects was observed in the treatment group as compared to the controls that received the GT 407 
sponges only. Specifically, the size of the defect was significantly reduced and, most 408 
importantly, a greater proportion of the repair tissue was hyaline cartilage than was observed 409 
in the controls. 410 
 411 
Conclusions 412 
Because of their chondrogenic ability, anti-inflammatory effects and lack of 413 
tumourigenicity, MSCs are an attractive prospect for stem cell-based therapies aimed at 414 
cartilage repair. Although the injection of MSC suspensions into the joint appears to retard 415 
the progression of osteoarthritis, at least in the short term, it is necessary to facilitate the 416 
engraftment of the new cartilage to the native cartilage and bone in order to affect significant 417 
physical repair of the damaged cartilage. Recent advances in tissue engineering offer the most 418 
promising results to date and are, at this stage, the most likely means of achieving significant, 419 
long-term, cartilage repair in patients with osteoarthritis. An important caveat, however, is 420 
that any instability or incongruity within the joint that was the impetus for the development of 421 
osteoarthritis in the first place must be addressed if repair of the damaged cartilage is to be 422 
maintained long-term. 423 
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 898 
Figure legends 899 
 900 
Fig.1. Schematic illustration of stem cell types of clinical relevance. Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are 901 
pluripotent, enabling them to give rise to all three germ layers of the embryo. Mesenchymal stem cells (MSCs), in contrast, are multipotent and 902 
predominantly differentiate into mesodermal derivatives including bone, cartilage, fat and muscle. It should be noted, however, that MSCs can 903 
also give rise to some derivatives of ectoderm (neural tissue) and endoderm (cells of liver and pancreas). 904 
  905 
Fig. 2. Schematic illustration of tissue engineering. Mesenchymal stem cells (MSCs) spatially supported by a matrix exhibit better engraftment 906 
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Significant increase in peak 
vertical force and vertical impulse 
in treated dogs vs. controls 




Elbow  Autologous stromal vascular 
fraction containing some putative 
Subjective assessments of 
lameness, pain, ROM 
6 months Subjective assessment that all 
dogs had improved lameness, pain  






AD-MSCs and ROM at 6 months 









hip dysplasia  
Autologous stromal vascular 
fraction containing some putative 
AD-MSCs 
Subjective assessments of 
lameness, pain, ROM 
3 months Subjective assessment that all 
dogs had improved lameness, pain 
and ROM at 3 months 








Control 1 (n=15) 
Control 2 (n=15) 
Stifle  7 x 10
6
 Human BM-MSCs 
suspended in PBS (Experiment 1) 
or HA (Experiment 2)  




5 weeks Partial cartilage repair in the 
experimental group receiving the 
BM-MSCs with HA, but not in the 
other groups 
 913 
Exp, experimental; Cont, control; AD-MSCs, adipose-derived MSCs; BM-MSCs, bone marrow-derived MSCs; PBS, phosphate buffered saline; 914 
HA, hyaluronic acid; ROM, range of motion.  915 
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Table 2 Summary of studies evaluating the therapeutic potential of mesenchymal stem cells in animals with experimentally-induced 916 
osteoarthritis 917 
 918 


































BM-MSCs mitigated development of post-traumatic OA during 2 
month study period 















3 months Tissue positive for GAG and collagen II immunostaining present in 
experimental, but not control, pigs. However, no engraftment of 
injected S-MSCs detected in repair tissue 













 (n = 
24) or 6 x 10
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6 months AD-MSCs retarded progression of OA. No engraftment of AD-
MSCs into endogenous cartilage 


















6 months Hyaline cartilage repair in both controls that received platelet-rich 
plasma gel and experimental animals that received platelet-rich 
plasma gels and S-MSCs 
Seo et al., 2013 Horse (n = 6) 
Contralateral 




defect in the 
lateral trochlear 

























4 months Osteochondral regeneration was observed in lesions treated with 
BM-MSC-sponge constructs, but not in joints that received sponges 
alone 
ter Huurne et Mouse Collagenase- 2 x 10
4
 Histological and 6 weeks When AD-MSCs were injected 7 days after collagenase treatment, 
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cartilage destruction was retarded compared to controls. In contrast, 
when AD-MSCs were injected 14 days after collagenase treatment, 
no effects were seen compared to controls. At 5 days after injection, 
no AD-MSCs could be detected 





















6 weeks Cartilage destruction was retarded in animals that received BM-
MSCs as compared to controls 

























7 weeks Animals treated with HA or HA and BM-MSCs showed 
statistically significant improvements in the healing of defects as 
compared to controls. There was no significant difference in defect 
healing between the HA and the HA and BM-MSC groups 
McIlwraith et 
al., 2011 
Horse (n = 10) 
Contralateral 
joint used as 
control 
Osteochondral 
















12 months No significant clinical improvement in the joints treated with BM-
MSCs as compared to controls; however, BM-MSC-treated joints 
showed an increase in the firmness of the repair tissue 



















5 months Rabbits that received AD-MSCs showed less cartilage 
degeneration, osteophyte formation and subchondral sclerosis than 
controls 






















6 months Osteochondral defects of the dogs that received the scaffolds 
seeded with chondrogenically-stimulated BM-MSCs showed 
significantly better cartilage repair than controls 






































4 months Rats that received non-transduced M-MSCs showed marked OA 
comparable to that observed in controls. However, rats that 
received BMP4- and Flt1-transduced M-MSCs repaired defects 
with hyaline cartilage 






















70 days No significant differences between experimental and control 
animals 























6 months Rabbits that received BM- MSCs seeded onto HA-based scaffolds 
formed hyaline-like cartilage within the defects to a more 
significant degree than the controls which received scaffolds alone 

















into defect (n 
= 12) or 
injected into 





6 months Cartilage regeneration was observed in animals in which the S-
MSCs were placed directly into the defect. In contrast, animals that 
received S-MSCs via injection into the joint showed no 
improvement compared to controls 

















3 months Improved cartilage healing in pigs that received BM-MSCs and HA 
as compared to controls that received saline or HA alone 




Wilke et al., 
2007 
Horse (n = 6) 
Contralateral 
















8 months No significant differences between BM-MSC-treated and control 
joints 



















 (n = 8) 
or 1 x 10
7






1 month Rats that received BM-MSCs showed no significant evidence of 
cartilage repair 



















5 months Goats that received BM-MSCs showed regeneration of the 
meniscus which helped retard the progression of the OA 
 919 
AD-MSCs, adipose-derived MSCs; BM-MSCs, bone marrow-derived MSCs; M-MSCs, muscle-derived MSCs; S-MSCs, synovium-derived 920 
MSCs; PBS, phosphate buffered saline; OA, osteoarthritis; HA, hyaluronic acid; GAG, glycosaminoglycans; BMP, bone morphogenetic protein.  921 
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